This targeted therapy, effective in the treatment of EGFR mutant non-small cell lung cancer, significantly improved overall survival in a clinical trial by over 8 months for patients with advanced disease when compared with older generation tyrosine kinase inhibitors [7]. Here, EGFR is linked to non-small cell lung carcinoma.